These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9848870)

  • 1. Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy.
    Mastronardi L; Puzzilli F; Guiducci A
    Neurosurgery; 1998 Dec; 43(6):1496. PubMed ID: 9848870
    [No Abstract]   [Full Text] [Related]  

  • 2. Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy.
    Hilton DA; Love S; Barber R; Ellison D; Sandeman DR
    Neurosurgery; 1998 Apr; 42(4):724-9. PubMed ID: 9574635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of molecular markers in low-grade diffuse astrocytomas: loss of p16 and retinoblastoma protein expression is associated with short survival.
    Hilton DA; Penney M; Evans B; Sanders H; Love S
    Am J Surg Pathol; 2002 Apr; 26(4):472-8. PubMed ID: 11914625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies.
    Ellison DW; Steart PV; Bateman AC; Pickering RM; Palmer JD; Weller RO
    J Neurol Neurosurg Psychiatry; 1995 Oct; 59(4):413-9. PubMed ID: 7561922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Postoperative radiation therapy of malignant glioma--results of conventional radiation therapy].
    Teshima T; Inoue T; Chatani M; Hata K; Taki T; Nii Y; Nakagawa H
    Nihon Gan Chiryo Gakkai Shi; 1987 Feb; 22(1):33-9. PubMed ID: 3611889
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular markers relating to malignant progression in Grade II astrocytoma.
    Yue WY; Yu SH; Zhao SG; Chen ZP
    J Neurosurg; 2009 Apr; 110(4):709-14. PubMed ID: 19025355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current status of radiation therapy in the treatment of malignant glioma:].
    Tanaka Y; Watari T; Takai Y; Niibe H; Kita M; Shimizu T; Takahashi M; Mitomo M; Jingu K; Maehara F
    Gan No Rinsho; 1989 Sep; 35(11):1233-9. PubMed ID: 2681870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of conventional radiotherapy in malignant gliomas:].
    Shibamoto Y; Yamashita J; Takahashi M; Yamasaki T; Kikuchi H; Abe M
    Gan No Rinsho; 1989 Sep; 35(11):1240-6. PubMed ID: 2554004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of optic pathway tumors of childhood.
    Wisoff JH
    Neurosurg Clin N Am; 1992 Oct; 3(4):791-802. PubMed ID: 1392576
    [No Abstract]   [Full Text] [Related]  

  • 10. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
    Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
    J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Possibilities of quantitative criteria of the effectiveness of treatment of glial brain tumors].
    Kachkov IA; Timofeeva TV
    Zh Vopr Neirokhir Im N N Burdenko; 1987; (4):37-40. PubMed ID: 3673429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis and p53 expression in human gliomas.
    Sipos L; Szegedi Z; Fedorcsák I; Afra D; Szende B
    Pathol Oncol Res; 1998; 4(4):267-70. PubMed ID: 9887356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas.
    Suzuki S; Oka H; Kawano N; Tanaka S; Utsuki S; Fujii K
    Brain Tumor Pathol; 2001; 18(2):151-4. PubMed ID: 11908872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDC25B, Ki-67, and p53 expressions in reactive gliosis and astrocytomas.
    Suren D; Isiksacan Ozen O
    J BUON; 2013; 18(4):1006-11. PubMed ID: 24344030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 immunohistochemical positivity as a prognostic marker in intracranial tumours.
    Soini Y; Niemelä A; Kamel D; Herva R; Bloigu R; Pääkkö P; Vähäkangas K
    APMIS; 1994 Oct; 102(10):786-92. PubMed ID: 7826609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locoregional approaches to therapy with gliomas as the paradigm.
    Liang BC; Weil M
    Curr Opin Oncol; 1998 May; 10(3):201-6. PubMed ID: 9619355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological correlation of cell proliferation, apoptosis and p53 in cerebellar pilocytic astrocytomas.
    Haapasalo H; Sallinen S; Sallinen P; Helén P; Jääskeläinen J; Salmi TT; Paetau A; Paljärvi L; Visakorpi T; Kalimo H
    Neuropathol Appl Neurobiol; 1999 Apr; 25(2):134-42. PubMed ID: 10216001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature.
    Reavey-Cantwell JF; Haroun RI; Zahurak M; Clatterbuck RE; Parker RJ; Mehta R; Fruehauf JP; Brem H
    J Neurooncol; 2001 Dec; 55(3):195-204. PubMed ID: 11859975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: corroborating clinical response in vitro: case report.
    Zhang W; Hinton DR; Surnock AA; Couldwell WT
    Neurosurgery; 1996 Mar; 38(3):587-90; discussion 590-1. PubMed ID: 8837815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoplasmic localization of wild-type p53 in glioblastomas correlates with expression of vimentin and glial fibrillary acidic protein.
    Sembritzki O; Hagel C; Lamszus K; Deppert W; Bohn W
    Neuro Oncol; 2002 Jul; 4(3):171-8. PubMed ID: 12084347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.